American Pharmaceutical Security Act

S. 5297 would direct the Administrator of the Centers for Medicare & Medicaid Services (CMS) to prepare and submit a report examining how existing coverage and reimbursement authorities could be used to protect the U.S. market for active pharmaceutical ingredients (APIs) and key starting materials — the raw chemical components used to manufacture prescription drugs. Beyond this reporting requirement, the specific contents, findings, or any policy changes the bill would mandate are not yet known, since the full legislative text has not been published.

The bill would primarily affect CMS, which would bear the reporting obligation, and by extension it touches the pharmaceutical manufacturing supply chain, since APIs and starting materials are core inputs to drug production. Because the bill's substantive provisions are not yet public, it is not possible to say with certainty how patients, drug manufacturers, or other stakeholders would be affected in practice.

The bill was introduced in the Senate on August 6, 2026, by Senator Adam Schiff (D-CA), and its status is currently "Introduced." The next steps would typically involve committee assignment and review; no further action has yet been recorded. Once the full text becomes available, a more detailed summary of its specific requirements and effects can be provided.

Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.